AZ, MSD’s Koselugo is first EU therapy for neurofibromatosisThe European Commission has approved AstraZeneca and MSD’s Koselugo for a rare genetic condition that causes tumours to Share XAZ, MSD’s Koselugo is first EU therapy for neurofibromatosishttps://pharmaphorum.com/news/az-msds-koselugo-is-first-eu-therapy-for-neurofibromatosis/
AstraZeneca, Merck cue up FDA verdict on selumetinib next yearAfter failing to make the grade in multiple cancer types, AstraZeneca and Merck & Co/MSD’s selumetinib could get Share XAstraZeneca, Merck cue up FDA verdict on selumetinib next yearhttps://pharmaphorum.com/news/astrazeneca-merck-cue-up-fda-verdict-on-selumetinib-next-year/
Neurofibromatosis treatment granted orphan status by EMAAstraZeneca and Merck & Co. announced the European Medicines Agency (EMA) has granted orphan designation to their codeveloped Share XNeurofibromatosis treatment granted orphan status by EMAhttps://pharmaphorum.com/news/nf1-treatment-granted-orphan-status-ema/
